FDA approves Hyrimoz, NVS’ Humira biosimilar: https://finance.yahoo.com/news/fda-approves-novartis-copy-abbvie-151406625.html NVS won’t launch Hyrimoz in the US until 9/20/23, based on a recently announced patent settlement (#msg-144157243).